Nanobiotix stock rebounds 7%, second-largest gain in SBF 120
The Parisian oncological nanomedicine biotech rebounds sharply in mid-afternoon, against the trend of a declining Paris market. This uptick occurs after a month of steep decline, which has wiped out most of the stock's technical levels.
The stock gains 6.95% to €20.16 versus €18.85 the previous day, while the SBF 120 falls 0.62% and the CAC 40 drops 0.61%. This increase places the value in second place in the index, just behind Genfit (+7.58%). It nonetheless only partially reduces a decline of 32.5% over one month, with the price remaining below its three moving averages: the gap is 15.5% with the 20-day MA at €23.87 and 32.1% with the 50-day MA at €29.69.
The RSI at 22.8, in oversold territory, summarizes the extent of the slide. The previous day, the stock had broken through its support level of €19.12. Today's rebound brings it back above this level, without the €18.85 support being called into question.
Cash reserves of €110.9 million financing operations until 2029
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
When publishing its financial update for the first half of 2026 on September 24, Nanobiotix reported €110.9 million in cash reserves. The company estimates this will allow it to finance its operations until 2029. This level includes the capital increase of approximately €86 million carried out in May, which brought liquidity well above the €52.8 million at the end of 2025.
The group is developing the radioamplifier NBTXR3 (JNJ-1900), associated with radiotherapy, in partnership with Johnson & Johnson. Nanobiotix is listed both in Paris and on the Nasdaq, where its ADSs (NBTX) trade at a one-to-one ratio with ordinary shares. The stock had lost more than 32% in one month at the previous close, and the nearest resistance level is at €32.5.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,6 millions d'euros
Quarterly revenue: 3,6 millions d'euros
Net income: -34,3 millions d'euros
Guidance from the release
« la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
